In Silico Assessment of Potential Geroprotectors: From Separate Endpoints to Complex Pharmacotherapeutic Effects.

This study presents an approach for the in silico assessment of potential geroprotectors that target the multifaceted mechanisms of aging, implemented in the PASS GERO web application. This work is timely given the societal impact of aging-the primary risk factor for major chronic diseases. The urgent need to extend healthspan-the period of life spent in good health-motivates the search for compounds that modulate fundamental aging mechanisms. The model estimates the probabilities of 117 aging-related biological activities with high predictive accuracy, achieving an average Invariant Accuracy of Prediction (IAP) of 0.967 under cross-validation. Validation using known geroprotectors (rapamycin, metformin, and resveratrol) demonstrated strong concordance between predicted activities and documented molecular mechanisms of action. For instance, the model correctly predicted rapamycin's inhibition of mTOR and metformin's activation of AMPK. The PASS GERO web application provides a systematic strategy to prioritize novel compound candidates for experimental evaluation in anti-aging research. We discuss challenges including the chemical diversity of the training data, the need for validated biomarkers, and the limitations of translating computational predictions into clinical outcomes, positioning the tool as robust application for activity profiling in discovery workflows.